A study published in the journal Cell Reports describes a new pathway related to the activity of receptors that are associated with several metabolic or cardiovascular diseases such as diabetes, obesity and hypertension. According to the conclusions, many antidiabetic effects of the activators of the PPARβ/δ receptors ─potential therapeutic targets for the treatment of type 2 diabetes─ are regulated by cytokine GDF15, a protein expressed under conditions of physiological stress.

The study contributes to find new therapeutic pathways for the treatment of metabolic dysfunctions and it is led by Professor Manuel Vázquez-Carrera, from the Faculty of Pharmacy and Food Sciences, the Institute of Biomedicine of the UB (IBUB), the Research Institute Sant Joan de Déu (IRSJD) and the Diabetes and Associated Metabolic Diseases Networking Biomedical Research Centre (CIBERDEM).

More